231 related articles for article (PubMed ID: 19395977)
1. Impact of multivessel stenting on top of percutaneous revascularization for unprotected left main disease in the drug-eluting stent era: insights from the Turin registry.
Sheiban I; Sillano D; Biondi-Zoccai G; Moretti C; Garrone P; Lombardi P; Sciuto F; Omedè P; Iacovino C; Spina CL; Trevi GP
J Cardiovasc Med (Hagerstown); 2009 Jun; 10(6):461-8. PubMed ID: 19395977
[TBL] [Abstract][Full Text] [Related]
2. Early and long-term results of percutaneous coronary intervention for unprotected left main trifurcation disease.
Sheiban I; Gerasimou A; Bollati M; Biondi-Zoccai G; Sciuto F; Omedé P; Sillano D; Trevi GP; Moretti C
Catheter Cardiovasc Interv; 2009 Jan; 73(1):25-31. PubMed ID: 19089932
[TBL] [Abstract][Full Text] [Related]
3. Outcomes and complications with off-label use of drug-eluting stents: results from the STENT (Strategic Transcatheter Evaluation of New Therapies) group.
Brodie BR; Stuckey T; Downey W; Humphrey A; Bradshaw B; Metzger C; Hermiller J; Krainin F; Juk S; Cheek B; Duffy P; Smith H; Edmunds J; Varanasi J; Simonton CA;
JACC Cardiovasc Interv; 2008 Aug; 1(4):405-14. PubMed ID: 19463338
[TBL] [Abstract][Full Text] [Related]
4. Results of percutaneous drug-eluting stent implantation for unprotected left main coronary disease according to left ventricular systolic function.
Bollati M; Gerasimou A; Sillano D; Biondi-Zoccai G; Garrone P; Moretti C; Sciuto F; Omedé P; Trevi GP; Sheiban I
Catheter Cardiovasc Interv; 2010 Mar; 75(4):586-93. PubMed ID: 20088012
[TBL] [Abstract][Full Text] [Related]
5. First generation versus new generation drug-eluting stents for the treatment of ostial/midshaft lesions in unprotected left main coronary artery: the Milan and New-Tokyo (MITO) registry.
Naganuma T; Chieffo A; Takagi K; Panoulas VF; Mitomo S; Sticchi A; Latib A; Miyazaki T; Sato K; Costopoulos C; Fujino Y; Montorfano M; Carlino M; Nakamura S; Colombo A
Catheter Cardiovasc Interv; 2015 Feb; 85(3):E63-9. PubMed ID: 25099758
[TBL] [Abstract][Full Text] [Related]
6. Impact of sex on 3-year outcome after percutaneous coronary intervention using bare-metal and drug-eluting stents in previously untreated coronary artery disease: insights from the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries.
Onuma Y; Kukreja N; Daemen J; Garcia-Garcia HM; Gonzalo N; Cheng JM; van Twisk PH; van Domburg R; Serruys PW;
JACC Cardiovasc Interv; 2009 Jul; 2(7):603-10. PubMed ID: 19628181
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes with cobalt-chromium bare-metal vs. drug-eluting stents: the REgistro regionale AngiopLastiche dell'Emilia-Romagna registry.
Manari A; Ortolani P; Guastaroba P; Marzaroli P; Menozzi M; Magnavacchi P; Varani E; Vignali L; Campo G; Marzocchi A
J Cardiovasc Med (Hagerstown); 2011 Feb; 12(2):102-9. PubMed ID: 20814313
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes of elective drug-eluting stenting of the unprotected left main coronary artery in patients with normal left ventricular function.
Lee MS; Yang T; Biondi-Zoccai G; Sillano D; Cerrato E; Tarantini G; Xhaxho J; Aragon J; Sheiban I
Catheter Cardiovasc Interv; 2011 Jun; 77(7):945-51. PubMed ID: 20824773
[TBL] [Abstract][Full Text] [Related]
9. Multicenter international registry of unprotected left main coronary artery percutaneous coronary intervention with drug-eluting stents in patients with myocardial infarction.
Lee MS; Sillano D; Latib A; Chieffo A; Zoccai GB; Bhatia R; Sheiban I; Colombo A; Tobis J
Catheter Cardiovasc Interv; 2009 Jan; 73(1):15-21. PubMed ID: 19089930
[TBL] [Abstract][Full Text] [Related]
10. Long-term risk of clinical events from stenting side branches of coronary bifurcation lesions with drug-eluting and bare-metal stents: an observational meta-analysis.
Zamani P; Kinlay S
Catheter Cardiovasc Interv; 2011 Feb; 77(2):202-12. PubMed ID: 20824754
[TBL] [Abstract][Full Text] [Related]
11. Impact of intravascular ultrasound imaging on early and late clinical outcomes following percutaneous coronary intervention with drug-eluting stents.
Claessen BE; Mehran R; Mintz GS; Weisz G; Leon MB; Dogan O; de Ribamar Costa J; Stone GW; Apostolidou I; Morales A; Chantziara V; Syros G; Sanidas E; Xu K; Tijssen JG; Henriques JP; Piek JJ; Moses JW; Maehara A; Dangas GD
JACC Cardiovasc Interv; 2011 Sep; 4(9):974-81. PubMed ID: 21939937
[TBL] [Abstract][Full Text] [Related]
12. Drug eluting stenting in bifurcation coronary lesions long-term results applying a systematic treatment strategy.
Assali AR; Vaknin-Assa H; Lev E; Teplitsky I; Dvir D; Brosh D; Bental T; Battler A; Kornowski R
Catheter Cardiovasc Interv; 2012 Mar; 79(4):615-22. PubMed ID: 22162218
[TBL] [Abstract][Full Text] [Related]
13. 2-year results of the AUTAX (Austrian Multivessel TAXUS-Stent) registry beyond the SYNTAX (synergy between percutaneous coronary intervention with TAXUS and cardiac surgery) study.
Gyöngyösi M; Christ G; Lang I; Kreiner G; Sochor H; Probst P; Neunteufl T; Badr-Eslam R; Winkler S; Nyolczas N; Posa A; Leisch F; Karnik R; Siostrzonek P; Harb S; Heigert M; Zenker G; Benzer W; Bonner G; Kaider A; Glogar D;
JACC Cardiovasc Interv; 2009 Aug; 2(8):718-27. PubMed ID: 19695539
[TBL] [Abstract][Full Text] [Related]
14. Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting.
Chacko R; Mulhearn M; Novack V; Novack L; Mauri L; Cohen SA; Moses J; Leon MB; Cutlip DE
JACC Cardiovasc Interv; 2009 Jun; 2(6):498-503. PubMed ID: 19539252
[TBL] [Abstract][Full Text] [Related]
15. Unprotected left main coronary artery stenting with zotarolimus (Endeavor) drug-eluting stents: a single center retrospective experience.
Simard T; Hibbert B; Chong AY; Ruchin P; Le May M; Labinaz M; Froeschl M; So D; Glover C; Marquis JF; O'Brien E
Catheter Cardiovasc Interv; 2012 Aug; 80(2):E15-22. PubMed ID: 21805580
[TBL] [Abstract][Full Text] [Related]
16. Five-year clinical outcomes after coronary stenting of chronic total occlusion using sirolimus-eluting stents: insights from the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital-(Research) Registry.
Shen ZJ; García-García HM; Garg S; Onuma Y; Schenkeveld L; van Domburg RT; Serruys PW;
Catheter Cardiovasc Interv; 2009 Dec; 74(7):979-86. PubMed ID: 19753636
[TBL] [Abstract][Full Text] [Related]
17. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents.
Park DW; Yun SC; Lee SW; Kim YH; Lee CW; Hong MK; Cheong SS; Kim JJ; Park SW; Park SJ
JACC Cardiovasc Interv; 2008 Oct; 1(5):494-503. PubMed ID: 19463351
[TBL] [Abstract][Full Text] [Related]
18. Comparison between one-stent versus two-stent technique for treatment of left main bifurcation lesions: A large single-center data.
Gao Z; Xu B; Yang Y; Qiao S; Wu Y; Chen T; Xu L; Yuan J; Chen J; Gao RL
Catheter Cardiovasc Interv; 2015 Jun; 85(7):1132-8. PubMed ID: 25614097
[TBL] [Abstract][Full Text] [Related]
19. The role of drug-eluting balloons alone or in combination with drug-eluting stents in the treatment of de novo diffuse coronary disease.
Costopoulos C; Latib A; Naganuma T; Sticchi A; Figini F; Basavarajaiah S; Carlino M; Chieffo A; Montorfano M; Naim C; Kawaguchi M; Giannini F; Colombo A
JACC Cardiovasc Interv; 2013 Nov; 6(11):1153-9. PubMed ID: 24262615
[TBL] [Abstract][Full Text] [Related]
20. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
